EP2377538A1 — Aqueous oral preparation of stable amlodipine
Assigned to MedRx Co Ltd · Expires 2011-10-19 · 15y expired
What this patent protects
The present invention aims to provide a stable aqueous oral preparation (liquid or jelly preparation) of amlosipine. The object aqueous oral preparation (jelly preparation) of amlodipine, which is stable and highly rapidly disintegratable, could be produced by using an anio…
USPTO Abstract
The present invention aims to provide a stable aqueous oral preparation (liquid or jelly preparation) of amlosipine. The object aqueous oral preparation (jelly preparation) of amlodipine, which is stable and highly rapidly disintegratable, could be produced by using an anionic surfactant having a sulfuric acid group or a sulfonic acid group as a stabilizer in an aqueous solution of amlodipine, preparing a liquid stable in the range of pH 5 - 7 as the liquid property, and adding and mixing a gelling agent, a fine powder solid and a gelling regulator. As a result, a novel oral preparation (liquid or jelly preparation) easy to take for older patients, who have declined swallowing function and face difficulty in taking tablets, can be provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.